Kynos Therapeutics

Kynos Therapeutics is a biopharmaceutical, VC-backed spin-out from the University of Edinburgh developing inhibitors of kynurenine 3-monooxygenase (KMO). KMO produces harmful metabolites during inflammation, and its inhibition prevents tissue injury. Kynos’s pipeline is focused on three key areas: critical illness post-surgery, chronic inflammatory conditions, and cancer.